Pharmacological treatments for thyroid eye disease

Drugs

Volumn 66, Issue 13, 2006, Pages 1685-1700

  Modjtahedi, Sara P ^a   Modjtahedi, Bobeck S ^a   Mansury, Ahmad M ^a   Selva, Dinesh ^b   Douglas, Raymond S ^a   Goldberg, Robert A ^a   Leibovitch, Igal ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANGIOPEPTIN; ANTIOXIDANT; ANTITHYROID AGENT; CORTICOSTEROID; CYCLOSPORIN; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; LIVER ENZYME; MEPREDNISONE; METHOTREXATE; NICOTINAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; PASIREOTIDE; PENTOXIFYLLINE; PREDNISONE; PROPYLTHIOURACIL; SOMATOSTATIN DERIVATIVE; THIAMAZOLE; TRIAMCINOLONE;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ARTHRALGIA; BLINDNESS; CHEMOSIS; CHOLECYSTITIS; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CREATININE BLOOD LEVEL; DECOMPRESSION SURGERY; DEPRESSION; DIPLOPIA; DISEASE SEVERITY; DIVERTICULITIS; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; ENDOCRINE OPHTHALMOPATHY; ENZYME BLOOD LEVEL; FATIGUE; GALLSTONE; GASTROINTESTINAL SYMPTOM; HAIR LOSS; HUMAN; HYPERESTHESIA; HYPERTENSION; INFRAORBITAL NERVE; INTRAOCULAR PRESSURE; IRRADIATION; LIVER FAILURE; LIVER INJURY; LIVER TOXICITY; MORBIDITY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE INFECTION; RADIATION DOSE; REVIEW; SIDE EFFECT; UNSPECIFIED SIDE EFFECT;

ADRENAL CORTEX HORMONES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; GRAVES OPHTHALMOPATHY; HUMANS; IMMUNOSUPPRESSIVE AGENTS;

EID: 33748886126     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666130-00003     Document Type: Review

References (109)

1. Wiersinga WM, Bartalena L. Epidemiology and prevention of Graves' ophthalmopathy. Thyroid 2002 Oct; 12 (10): 855-60
2. Yamada M, Li AW, Wall JR. Thyroid-associated ophthalmopathy: clinical features, pathogenesis, and management. Crit Rev Clin Lab Sci 2000 Dec; 37 (6): 523-49
3. Marcocci C, Bartalena L, Marino M, et al. Current medical management of Graves ophthalmopathy. Ophthal Plast Reconstr Surg 2002 Nov; 18 (6): 402-8
4. Perros P, Crombie AL, Kendall-Taylor P. Natural history of thyroid associated ophthalmopathy. Clin Endocrinol (Oxf) 1995 Jan; 42 (1): 45-50
5. El-Kaissi S, Frauman AG, Wall JR. Thyroid-associated ophthalmopathy: a practical guide to classification, natural history and management. Intern Med J 2004 Aug; 34 (8): 482-91
6. Bahn RS. Clinical review 157: pathophysiology of Graves' ophthalmopathy: the cycle of disease. J Clin Endocrinol Metab 2003 May; 88 (5): 1939-46
7. Ludgate M, Baker G. Inducing Graves' ophthalmopathy. J Endocrinol Invest 2004 Mar; 27 (3): 211-5
8. McLachlan SM, Bahn R, Rapoport B. Endocrine ophthalmopathy: a re-evaluation of the association with thyroid autoantibodies. Autoimmunity 1992; 14 (2): 143-8
9. Bahn RS, Heufelder AE. Pathogenesis of Graves' ophthalmopathy. N Engl J Med 1993 Nov 11; 329 (20): 1468-75
10. Bartalena L, Wiersinga WM, Pinchera A. Graves' ophthalmopathy: state of the art and perspectives. J Endocrinol Invest 2004 Mar; 27 (3): 295-301
11. de Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metab 1993 Nov; 77 (5): 1120-4
12. Campbell RJ. Pathology of Graves' ophthalmopathy. In: Gorman CA, Waller RR, Dyer JA, editors. The eye and orbit in thyroid disease. New York: Raven Press, 1984: 25-31
13. Campbell RJ. Immunology of Graves' ophthalmopathy: retrobulbar histology, histochemistry. Acta Endocrinol 1989; 121 Suppl. 2: 9-16
14. Smith TJ, Bahn RS, Gorman CA. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr Rev 1989 Aug; 10 (3): 366-91
15. Bahn RS, Heufelder AE. Retroocular fibroblasts: important effector cells in Graves' ophthalmopathy. Thyroid 1992; 2 (1): 89-94
16. Prabhakar BS, Bahn RS, Smith TJ. Current perspective on the pathogenesis of Graves' disease and ophthalmopathy. Endocr Rev 2003 Dec; 24 (6): 802-35
17. Metcalfe RA, Weetman AP. Stimulation of extraocular muscle fibroblasts by cytokines and hypoxia: possible role in thyroid-associated ophthalmopathy. Clin Endocrinol (Oxf) 1994 Jan; 40 (1): 67-72
18. Gianoukakis AG, Douglas RS, King CS, et al. IgG from patients with Graves' disease induces IL-16 and RANTES expression in cultured human thyrocytes: a putative mechanism for T cell infiltration of the thyroid in autoimmune disease. Endocrinology 2006 Apr; 147 (4): 1941-9
19. Sautter-Bihl ML. Orbital radiotherapy: recent experience in Europe. In: Wall JR, How J, editors. Graves' ophthalmolpathy. Cambridge: Blackwell, 1990: 145-157
20. Bartalena L, Marcocci C, Manetti L, et al. Orbital radiotherapy for Graves' ophthalmopathy. Thyroid 1998 May; 8 (5): 439-41
21. Behbehani R, Sergott RC, Savino PJ. Orbital radiotherapy for thyroid-related orbitopathy. Curr Opin Ophthalmol 2004 Dec; 15 (6): 479-82
22. Mourits MP, van Kempen-Harteveld ML, Garcia MB, et al. Radiotherapy for Graves' orbitopathy: randomised placebo-controlled study. Lancet 2000 Apr 29; 355 (9214): 1505-9
23. Marcocci C, Bartalena L, Rocchi R, et al. Long-term safety of orbital radiotherapy for Graves' ophthalmopathy. J Clin Endocrinol Metab 2003 Aug; 88 (8): 3561-6
24. Gorman CA, Garrity JA, Fatourechi V, et al. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology 2001 Sep; 108 (9): 1523-34
25. Goh MS, McNab AA. Orbital decompression in Graves' orbitopathy: efficacy and safety. Intern Med J 2005 Oct; 35 (10): 586-91
26. Goldberg RA, Weinberg DA, Shorr N, et al. Maximal, three-wall, orbital decompression through a coronal approach. Ophthalmic Surg Lasers 1997 Oct; 28 (10): 832-43
27. Kalmann R, Mourits MP, van der Pol JP, et al. Coronal approach for rehabilitative orbital decompression in Graves' ophthalmopathy. Br J Ophthalmol 1997 Jan; 81 (1): 41-5
28. Ulualp SO, Massaro BM, Toohill RJ. Course of proptosis in patients with Graves' disease after endoscopic orbital decompression. Laryngoscope 1999 Aug; 109 (8): 1217-22
29. Goldberg RA, Shorr N, Cohen MS. The medical orbital strut in the prevention of postdecompression dystopia in dysthyroid ophthalmopathy. Ophthal Plast Reconstr Surg 1992; 8 (1): 32-4
30. Wiersinga WM, Smit T, Schuster-Uittenhoeve AL, et al. Therapeutic outcome of prednisone medication and of orbital irradiation in patients with Graves' ophthalmopathy. Ophthalmologica 1988; 197 (2): 75-84
31. Bartalena L, Pinchera A, Marcocci C. Management of Graves' ophthalmopathy: reality and perspectives. Endocr Rev 2000 Apr; 21 (2): 168-99
32. Wiersinga WM, Prummel MF, Terwee CB. Effects of Graves' ophthalmopathy on quality of life. J Endocrinol Invest 2004 Mar; 27 (3): 259-64
33. Wiersinga WM. Immunosuppressive treatment of Graves' ophthalmopathy. Thyroid 1992; 2 (3): 229-33
34. Brauer VF, Scholz GH. Treatment of Graves' ophthalmopathy with oral or intravenous corticosteroids. Med Klin 2004 Feb 15; 99 (2): 71-6
35. Marcocci C, Bartalena L, Tanda ML, et al. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study. J Clin Endocrinol Metab 2001 Aug; 86 (8): 3562-7
36. Ohtsuka K, Sato A, Kawaguchi S, et al. Effect of steroid pulse therapy with and without orbital radiotherapy on Graves' ophthalmopathy. Am J Ophthalmol 2003 Mar; 135 (3): 285-90
37. Koshiyama H, Koh T, Fujiwara K, et al. Therapy of Graves' ophthalmopathy with intravenous high-dose steroid followed by orbital irradiation. Thyroid 1994; 4 (4): 409-13
38. Kendall-Taylor P, Crombie AL, Stephenson AM, et al. Intravenous methylprednisolone in the treatment of Graves' ophthalmopathy. BMJ 1988 Dec 17; 297 (6663): 1574-8
39. Hiromatsu Y, Tanaka K, Sato M, et al. Intravenous methyl-prednisolone pulse therapy for Graves' ophthalmopathy. Endocr J 1993 Feb; 40 (1): 63-72
40. Matejka G, Verges B, Vaillant G, et al. Intravenous methyl-prednisolone pulse therapy in the treatment of Graves' ophthalmopathy. Horm Metab Res 1998 Feb; 30 (2): 93-8
41. Kahaly GJ, Pitz S, Hommel G, et al. Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves' orbitopathy. J Clin Endocrinol Metab 2005 Sep; 90 (9): 5234-40
42. Macchia PE, Bagattini M, Lupoli G, et al. High-dose intravenous corticosteroid therapy for Graves' ophthalmopathy. J Endocrinol Invest 2001 Mar; 24 (3): 152-8
43. Hart RH, Kendall-Taylor P, Crombie A, et al. Early response to intravenous glucocorticoids for severe thyroid-associated ophthalmopathy predicts treatment outcome. J Ocul Pharmacol Ther 2005 Aug; 21 (4): 328-36
44. Wakelkamp IM, Baldeschi L, Saeed P, et al. Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves' ophthalmopathy? A randomized controlled trial. Clin Endocrinol (Oxf) 2005 Sep; 63 (3): 323-8
45. Marino M, Morabito E, Brunetto MR, et al. Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves' ophthalmopathy. Thyroid 2004; 14: 403-6
46. Ebner R, Devoto MH, Weil D, et al. Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone. Br J Ophthalmol 2004 Nov; 88 (11): 1380-6
47. Poonyathalang A, Preechawat P, Charoenkul W, et al. Retrobulbar injection of triamcinolone in thyroid associated orbitopathy. J Med Assoc Thai 2005 Mar; 88 (3): 345-9
48. Marcocci C, Bartalena L, Panicucci M, et al. Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves' ophthalmopathy: a comparative study. Clin Endocrinol (Oxf) 1987 Jul; 27 (1): 33-42
49. Pinchera A, Marcocci C, Bartalena L, et al. Orbital cobalt radiotherapy and systemic or retrobulbar corticosteroids for Graves' ophthalmopathy. Horm Res 1987; 26 (1-4): 177-83
50. Thomas ID, Hart JK. Retrobulbar repository corticosteroid therapy in thyroid ophthalmopathy. Med J Aust 1974 Sep 28; 2 (13): 484-7
51. Ivy HK. Medical approach to ophthalmopathy of Graves' disease. Mayo Clin Proc 1972 Dec; 47 (12): 980-5
52. Garber MI. Methylprednisolone in the treatment of exophthalmos. Lancet 1966 Apr 30; 1 (7444): 958-60
53. Gebertt S. Depot-methylprednisolone for subconjunctival and retrobulbar injections. Lancet 1961 Aug 12; 2: 344-5
54. Goldberg RA. Orbital steroid injections. Br J Ophthalmol 2004 Nov; 88 (11): 1359-60
55. Giles CL. Bulbar perforation during periocular injection of corticosteroids. Am J Ophthalmol 1974 Apr; 77 (4): 438-41
56. Schlaegel TF, Wilson FM. Accidental intraocular injection of depot corticosteroids. Trans Am Acad Ophthalmol Otolaryngol 1974; 78: 847-55
57. Hosal BM, Zilelioglu G. Ocular complication of intralesional corticosteroid injection of a chalazion. Eur J Ophthalmol 2003 Nov-Dec; 13 (9-10): 798-9
58. Jabs DA. A prospective evaluation of subconjunctival injection of triamcinolone acetonide for resistant anterior scleritis [discussion by Dr A Jabs]. Ophthalmology 2002; 109: 806-7
59. Agrawal S, Agrawal J, Agrawal TP. Conjunctival ulceration following triamcinolone injection. Am J Ophthalmol 2003 Sep; 136 (3): 539-40
60. Fogla R, Rao SK, Biswas J. Avoiding conjunctival necrosis after periocular depot corticosteroid injection. J Cataract Refract Surg 2000 Feb; 26 (2): 163-4
61. Moshfeghi DM, Lowder CY, Roth DB, et al. Retinal and choroidal vascular occlusion after posterior sub-tenon triamcinolone injection. Am J Ophthalmol 2002 Jul; 134 (1): 132-4
62. Ellis PP. Occlusion of the central retinal artery after retrobulbar corticosteroid injection. Am J Ophthalmol 1978 Mar; 85 (3): 352-6
63. Shorr N, Seiff SR. Central retinal artery occlusion associated with periocular corticosteroid injection for juvenile hemangioma. Ophthalmic Surg 1986 Apr; 17 (4): 229-31
64. Mabry RL. Visual loss after intranasal corticosteroid injection. Incidence, causes, and prevention. Arch Otolaryngol 1981 Aug; 107 (8): 484-6
65. McGrew RN, Wilson RS, Havener WH. Sudden blindness secondary to injections of common drugs in the head and neck: I. clinical experiences. Otolaryngology 1978 Jan-Feb; 86 (1): ORL-147-51
66. McCleve DE, Goldstein JC. Blindness secondary to injections in the nose, mouth, and face: cause and prevention. Ear Nose Throat J 1995 Mar; 74 (3): 182-8
67. McLean EB. Inadvertent injection of corticosteroid into the choroidal vasculature. Am J Ophthalmol 1975 Nov; 80 (5): 835-7
68. Thomas EL, Laborde RP. Retinal and choroidal vascular occlusion following intralesional corticosteroid injection of a chalazion. Ophthalmology 1986 Mar; 93 (3): 405-7
69. Gupta OP, Boynton JR, Sabini P, et al. Proptosis after retrobulbar corticosteroid injections. Ophthalmology 2003 Feb; 110 (2): 443-7
70. Nozik RA. Orbital rim fat atrophy after repository periocular corticosteroid injection. Am J Ophthalmol 1976 Dec; 82 (6): 928-30
71. Smith JR, George RK, Rosenbaum JT. Lower eyelid herniation of orbital fat may complicate periocular corticosteroid injection. Am J Ophthalmol 2002 Jun; 133 (6): 845-7
72. Herschler J. Intractable intraocular hypertension induced by repository triamcinolone acetonide. Am J Ophthalmol 1972 Sep; 74 (3): 501-4
73. Marcocci C, Bartalena L, Bogazzi F, et al. Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves' ophthalmopathy is more effective than radiotherapy alone: results of prospective randomized study. J Endocrinol Invest 1991; 14: 853-60
74. Bartalena L, Marcocci C, Chiovato L, et al. Orbital cobalt irradiation combined with systemic corticosteroids for Graves' ophthalmopathy: comparison with systemic corticosteroids alone. J Clin Endocrinol Metab 1983; 56: 1139-44
75. Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998 Jan 8; 338: 73-8
76. Krassas GE, Heufelder AE. Immunosuppressive therapy in patients with thyroid eye disease: an overview of current concepts. Eur J Endocrinol 2001 Apr; 144 (4): 311-8
77. Kahaly G, Schrezenmeir J, Krause U, et al. Ciclosporin and prednisone vs prednisone in treatment of Graves' ophthalmopathy: a controlled, randomized and prospective study. Eur J Clin Invest 1986 Oct; 16 (5): 415-22
78. Leovey A, Bako G, Szabo J, et al. Combined cyclosporin-A and methylprednisolone treatment of Graves' ophthalmopathy. Acta Med Hung 1992-93; 49 (3-4): 179-85
79. Prummel MF, Mourits MP, Berghout A, et al. Prednisone and cyclosporine in the treatment of severe Graves' ophthalmopathy. N Engl J Med 1989 Nov 16; 321 (20): 1353-9
80. Bahn RS. Understanding the immunology of Graves' ophthalmopathy: is it an autoimmune disease? Endocrinol Metab Clin North Am 2000 Jun; 29 (2): 287-96
81. Heufelder AE, Schworm HD, Heufelder G. Methotrexate in the treatment of refractory Graves' ophthalmopathy [abstract no. O-002]. 12th International Thyroid Congress; 2000 Oct 22-27; Kyoto, Japan
82. Smith JR, Rosenbaum JT. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001 Oct; 85 (10): 1220-4
83. Bartalena L, Marcocci C, Pinchera A. Somatostatin analogs for Graves' ophthalmopathy: do they bounce off like a rubber producbullet? J Clin Endocrinol Metab 2004 Dec; 89 (12): 5908-9
84. Krassas GE. Somatostatin analogs: a new tool for the management of Graves' ophthalmopathy. J Endocrinol Invest 2004 Mar; 27 (3): 281-7
85. Wemeau JL, Caron P, Beckers A, et al. Octreotide (long-acting release formulation) treatment in patients with graves' orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study. J Clin Endocrinol Metab 2005 Feb; 90 (2): 841-8
86. Wiersinga WM, Prummel MF, Mourits MP, et al. Classification of eyesigns of Graves. Thyroid 1991; 1 (4): 357-60
87. Mourits MP, Koornneef L, Wiersinga WM, et al. Clinical criteria for the assessment of disease activity in Graves' ophthalmopathy: a novel approach. Br J Ophthalmol 1989; 73: 639-44
88. Dickinson AJ, Vaidya B, Miller M, et al. Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 2004 Dec; 89 (12): 5910-5
89. Pasquali D, Notaro A, Bonavolonta' G, et al. Somatostatin receptor genes are expressed in lymphocytes from retroorbital tissues in Graves' disease. J Clin Endocrinol Metab 2002 Nov; 87 (11): 5125-9
90. Pasquali D, Vassallo P, Esposito D, et al. Somatostatin receptor gene expression and inhibitory effects of octreotide on primary cultures of orbital fibroblasts from Graves' ophthalmopathy. J Mol Endocrinol 2000 Aug; 25 (1): 63-71
91. Saveanu A, Gunz G, Dufour H, et al. Distribution and functionality of the somatostatin receptor subtypes in acromegaly. J Endocrinol Invest 2003; 26 (8 Suppl.): 4-7
92. Boerlin V, van der Hoek J, Beglinger CH, et al. New insights on SOM230, a universal somatostatin receptor ligand. J Endocrinol Invest 2003; 26 (8 Suppl.): 14-6
93. Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol 2002 May; 146 (5): 707-16
94. Hegedius L, Brix TH, Vestergaard P. Relationship between cigarette smoking and Graves' ophthalmopathy. J Endocrinol Invest 2004 Mar; 27 (3): 265-71
95. Shine B, Fells P, Edwards OM, et al. Association between Graves' ophthalmopathy and smoking. Lancet 1990 May 26; 335 (8700): 1261-3
96. Hagg E, Asplund K. Is endocrine ophthalmopathy related to smoking? BMJ (Clin Res Ed) 1987 Sep 12; 295 (6599): 634-5
97. Bouzas EA, Karadimas P, Mastorakos G, et al. Antioxidant agents in the treatment of Graves' ophthalmopathy. Am J Ophthalmol 2000 May; 129 (5): 618-22
98. Lu R, Wang P, Wartofsky L, et al. Oxygen free radicals in interleukin-1beta-induced glycosaminoglycan production by retro-ocular fibroblasts from normal subjects and Graves' ophthalmopathy patients. Thyroid 1999 Mar; 9 (3): 297-303
99. Heufelder AE, Wenzel BE, Bahn RS. Methimazole and propylthiouracil inhibit the oxygen free radical-induced expression of a 72 kilodalton heat shock protein in Graves' retroocular fibroblasts. J Clin Endocrinol Metab 1992 Apr; 74 (4): 737-42
100. Burch HB, Lahiri S, Bahn RS, et al. Superoxide radical production stimulates retroocular fibroblast proliferation in Graves' ophthalmopathy. Exp Eye Res 1997 Aug; 65 (2): 311-6
101. Bartalena L, Tanda ML, Piantanida E, et al. Oxidative stress and Graves' ophthalmopathy: in vitro studies and therapeutic implications. Biofactors 2003; 19 (3-4): 155-63
102. Balazs C, Kiss E, Vamos A, et al. Beneficial effect of pentoxifylline on thyroid associated ophthalmopathy (TAO)*: a pilot study [published erratum appears in J Clin Endocrinol Metab 1997 Sep; 82 (9): 3077]. J Clin Endocrinol Metab 1997 Jun; 82 (6): 1999-2002
103. Finamor FE, Martins JR, Nakanami D, et al. Pentoxifylline (PTX): an alternative treatment in Graves' ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial. Eur J Ophthalmol 2004 Jul-Aug; 14 (4): 277-83
104. Krassas GE, Pontikides N, Doukidis D, et al. Serum levels of tumor necrosis factor-alpha, soluble intercellular adhesion molecule-1, soluble vascular cell adhesion molecule-1, and soluble interleukin-1 receptor antagonist in patients with thyroid eye disease undergoing treatment with somatostatin analogues. Thyroid 2001 Dec; 11 (12): 1115-22
105. Paridaens D, van den Bosch WA, van der Loos TL, et al. The effect of etanercept on Graves' ophthalmopathy: a pilot study. Eye 2005 Dec; 19 (12): 1286-9
106. Durrani OM, Reuser TQ, Murray PI. Infliximab: a novel treatment for sight-threatening thyroid associated ophthalmopathy. Orbit 2005 Jun; 24 (2): 117-9
107. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999 Jan 28; 340 (4): 253-9
108. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997 Jul 17; 337 (3): 141-7
109. Bartalena L. Editorial: glucocorticoids for Graves' ophthalmopathy: how and when. J Clin Endocrinol Metab 2005 Sep; 90 (9): 5497-9